| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.21 | 2e-05 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.2 | 5e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.19 | 5e-05 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.18 | 8e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.19 | 0.0005 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.16 | 0.004 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.072 | 0.1 |